Skip to main content Accessibility help
  • Print publication year: 2011
  • Online publication date: August 2011

24 - Mitochondrial disorders


1. Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 2008; 4: 600–9.
2. Finsterer J. Mitochondrial disorders, cognitive impairment and dementia. J Neurol Sci 2009; 283: 143–8.
3. Schaefer A, McFarland R, Blakely E et al. Prevalence of mitochondrial DNA disease in adults. Ann Neurol 2008; 63: 35–9.
4. Chinnery P, Johnson M, Wardell T et al. The epidemiology of pathogenic mitochondrial DNA mutations. Ann Neurol 2000; 48: 188–93.
5. Skladal D, Halliday J, Thorburn D. Minimum birth prevalence of mitochondrial respiratory chain disorders in children. Brain 2003; 126: 1905–12.
6. DiMauro S, Schon E. Mitochondrial disorders in the nervous system. Annu Rev Neurosci 2008; 31: 91–123.
7. Robinson B. Lactic acidemia and mitochondrial disease. Mol Genet Metab 89: 3–13.
8. Kaufmann P, Shungu D, Sano M et al. Cerebral lactic acidosis correlates with neurological impairment in MELAS. Neurology 2004; 62: 1297–302.
9. Sciacco M, Bonilla E, Schon E et al. Distribution of wild-type and common deletion forms of mtDNA in normal and respiration-deficient muscle fibers from patients with mitochondrial myopathy. Hum Mol Genet 1994; 3: 13–19.
10. Taylor R, Schaefer A, Barron M et al. The diagnosis of mitochondrial muscle disease. Neuromuscul Disord 2004; 14: 237–45.
11. Hudson G, Chinnery P. Mitochondrial DNA polymerase-gamma and human disease. Hum Mol Genet 2006; 15(Spec No 2): R244–52.
12. DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med, 2003; 348: 2656–68.
13. Wai T, Teoli D, Shoubridge E. The mitochondrial DNA genetic bottleneck results from replication of a subpopulation of genomes. Nat Genet 2008; 40: 1484–8.
14. Cree L, Samuels D, de Sousa Lopes S et al. A reduction of mitochondrial DNA molecules during embryogenesis explains the rapid segregation of genotypes. Nat Genet 2008; 40: 249–54.
15. Simon D, Johns D. Mitochondrial disorders: clinical and genetic features. Annu Rev Med 1999; 50: 111–27.
16. Graziewicz M, Longley M, Copeland W. DNA polymerase gamma in mitochondrial DNA replication and repair. Chem Rev 2006; 106: 383–405.
17. Winterthun S, Ferrari G, He L et al. Autosomal recessive mitochondrial ataxic syndrome due to mitochondrial polymerase gamma mutations. Neurology 2005; 64: 1204–8.
18. Milone M, Brunetti-Pierri N, Tang L et al. Sensory ataxic neuropathy with ophthalmoparesis caused by POLG mutations. Neuromuscul Disord 2008; 18: 626–32.
19. Bohlega S, Tanji K, Santorelli F et al. Multiple mitochondrial DNA deletions associated with autosomal recessive ophthalmoplegia and severe cardiomyopathy. Neurology 1996; 46: 1329–34.
20. Van Goethem G, Dermaut B, Löfgren A et al. Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. Nat Genet 2001; 28: 211–12.
21. Hudson G, Schaefer AM, Taylor RW et al. Mutation of the linker region of the polymerase gamma-1 (POLG1) gene associated with progressive external ophthalmoplegia and Parkinsonism. Arch Neurol 2007; 64: 553–7.
22. Mohr J, Mageroy K. Sex-linked deafness of a possibly new type. Acta Genet Stat Med 1960; 10: 54–62.
23. Tranebjaerg L, Schwartz C, Eriksen H et al. A new X linked recessive deafness syndrome with blindness, dystonia, fractures, and mental deficiency is linked to Xq22. J Med Genet 1995; 32: 257–63.
24. Merchant S, McKenna M, Nadol JJ et al. Temporal bone histopathologic and genetic studies in Mohr-Tranebjaerg syndrome (DFN-1). Otol Neurotol 2001; 22: 506–11.
25. Roesch K, Curran S, Tranebjaerg L et al. Human deafness dystonia syndrome is caused by a defect in assembly of the DDP1/TIMM8a-TIMM13 complex. Hum Mol Genet 2002; 11: 477–86.
26. Binder J, Hofmann S, Kreisel S et al. Clinical and molecular findings in a patient with a novel mutation in the deafness-dystonia peptide (DDP1) gene. Brain 2003; 126: 1814–20.
27. Lamperti C, Naini A, Hirano M et al. Cerebellar ataxia and coenzyme Q10 deficiency. Neurology 2003; 60: 1206–8.
28. Schon E, DiMauro S. Mitochondrial mutations: genotype to phenotype. Novartis Found Symp 2007; 287: 214–25; discussion 226–33.
29. Kirkman M, Yu-Wai-Man P, Korsten A et al. Gene-environment interactions in Leber hereditary optic neuropathy. Brain 2009; 132: 2317–26.
30. Yang J, Zhu Y, Tong Y et al. Confirmation of the mitochondrial ND1 gene mutation G3635A as a primary LHON mutation. Biochem Biophys Res Commun 2009; 386: 50–4.
31. Liang M, Guan M, Zhao F et al. Leber’s hereditary optic neuropathy is associated with mitochondrial ND1 T3394C mutation. Biochem Biophys Res Commun 2009; 383: 286–92.
32. Johns D. Seminars in medicine of the Beth Israel Hospital, Boston. Mitochondrial DNA and disease. N Engl J Med 1995; 333: 638–44.
33. Novotny EJ, Singh G, Wallace D et al. Leber’s disease and dystonia: a mitochondrial disease. Neurology 1986; 36: 1053–60.
34. Watanabe Y, Odaka M, Hirata K. Case of Leber’s hereditary optic neuropathy with mitochondrial DNA 11778 mutation exhibiting cerebellar ataxia, dilated cardiomyopathy and peripheral neuropathy. Brain Nerve 2009; 61: 309–12.
35. Bonnet C, Augustin S, Ellouze S et al. The optimized allotopic expression of ND1 or ND4 genes restores respiratory chain complex I activity in fibroblasts harboring mutations in these genes. Biochim Biophys Acta 2008; 1783: 1707–17.
36. Man P, Turnbull D, Chinnery P. Leber hereditary optic neuropathy. J Med Genet 2002; 39: 162–9.
37. Perez F, Anne O, Debruxelles S et al. Leber’s optic neuropathy associated with disseminated white matter disease: a case report and review. Clin Neurol Neurosurg 2009; 111: 83–6.
38. Sala G, Trombin F, Beretta S et al. Antioxidants partially restore glutamate transport defect in Leber hereditary optic neuropathy cybrids. J Neurosci Res 2008; 86: 3331–7.
39. Matthews P, Marchington D, Squier M et al. Molecular genetic characterization of an X-linked form of Leigh’s syndrome. Ann Neurol 1993; 33: 652–5.
40. Loeffen J, Smeitink J, Triepels R et al. The first nuclear-encoded complex I mutation in a patient with Leigh syndrome. Am J Hum Genet 1998; 63: 1598–608.
41. Wang J, Brautbar A, Chan A et al. Two mtDNA mutations 14487T>C (M63V, ND6) and 12297T>C (tRNA Leu) in a Leigh syndrome family. Mol Genet Metab 2009; 96: 59–65.
42. Santorelli F, Shanske S, Macaya A et al. The mutation at nt 8993 of mitochondrial DNA is a common cause of Leigh’s syndrome. Ann Neurol 1993; 34: 827–34.
43. Lee H, Tsai C, Chi C et al. Leigh syndrome: clinical and neuroimaging follow-up. Pediatr Neurol 2009; 40: 88–93.
44. Saneto R, Friedman S, Shaw D. Neuroimaging of mitochondrial disease. Mitochondrion 2008; 8: 396–413.
45. Leigh D. Subacute necrotizing encephalomyelopathy in an infant. J Neurol Neurosurg Psychiatry 1951; 14: 216–21.
46. Horvath R, Hudson G, Ferrari G et al. Phenotypic spectrum associated with mutations of the mitochondrial polymerase gamma gene. Brain 2006; 129: 1674–84.
47. Ruiz-Pesini E, Lott M, Procaccio V et al. An enhanced MITOMAP with a global mtDNA mutational phylogeny. Nucleic Acids Res 2007; 35: D823–8.
48. Shibasaki H, Yamashita Y, Neshige R et al. Pathogenesis of giant somatosensory evoked potentials in progressive myoclonic epilepsy. Brain 1985; 108: 225–40.
49. Mongini T, Doriguzzi C, Chiadò-Piat L et al. MERRF/MELAS overlap syndrome in a family with A3243G mtDNA mutation. Clin Neuropathol 21: 72–6.
50. Holt I, Harding A, Petty R et al. A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am J Hum Genet 1990; 46: 428–33.
51. Haas R, Dietrich R. Neuroimaging of mitochondrial disorders. Mitochondrion 2004; 4: 471–90.
52. Finsterer J. Treatment of mitochondrial disorders. Eur J Paediatr Neurol 14: 29–44.
53. Lim LL, Ahmed A. Limited efficacy of levetiracetam on myoclonus of different etiologies. Parkinsonism Relat Disord 2005; 11: 135–7.
54. Mancuso M, Galli R, Pizzanelli C et al. Antimyoclonic effect of levetiracetam in MERRF syndrome. J Neurol Sci 2006; 243: 97–9.
55. Leung TF, Hui J, Yeung WL et al. A Chinese girl with Leigh syndrome: effect of botulinum toxin on dystonia. J Paediatr Child Health 1998; 34: 480–2.
56. Murphy J, Blakely E, Schaefer A et al. Resistance training in patients with single, large-scale deletions of mitochondrial DNA. Brain 2008; 131: 2832–40.
57. Sanaker P, Husebye E, Fondenes O et al. Clinical evolution of Kearns–Sayre syndrome with polyendocrinopathy and respiratory failure. Acta Neurol Scand Suppl 2007; 187: 64–7.
58. Rodriguez MC, MacDonald JR, Mahoney DJ et al. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 2007; 35: 235–42.
59. Spindler M, Beal MF, Henchcliffe C. Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatr Dis Treat 2009; 5: 597–610.
60. Chinnery P, MaJAMAa K, Turnbull D et al. Treatment for mitochondrial disorders. Cochrane Database Syst Rev 2006; CD004426.
61. Kyriakouli D, Boesch P, Taylor R et al. Progress and prospects: gene therapy for mitochondrial DNA disease. Gene Ther 2008; 15: 1017–23.
62. Manfredi G, Fu J, Ojaimi J et al. Rescue of a deficiency in ATP synthesis by transfer of MTATP6, a mitochondrial DNA-encoded gene, to the nucleus. Nat Genet 2002; 30: 394–9.
63. Mahata B, Mukherjee S, Mishra S et al. Functional delivery of a cytosolic tRNA into mutant mitochondria of human cells. Science 2006; 314: 471–4.
64. Minczuk M, Papworth M, Miller J et al. Development of a single-chain, quasi-dimeric zinc-finger nuclease for the selective degradation of mutated human mitochondrial DNA. Nucleic Acids Res 2008; 36: 3926–38.